| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00185-7400-14 | 00185-7400 | Leuprolide Acetate | Leuprolide Acetate | 1.0 mg/.2mL | Hormonal Therapy | GnRH Agonist | Subcutaneous | Jan 6, 2011 | In Use | ||
| 80425-0075-02 | 80425-0075 | Ondansetron HCL | Ondansetron HCL | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 31, 2007 | In Use | |
| 60505-3802-08 | 60505-3802 | Nilotinib | Nilotinib | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Mar 25, 2025 | In Use | |
| 68788-8819-05 | 68788-8819 | PREDNISONE | PREDNISONE | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 23, 2025 | In Use | |
| 63187-0379-07 | 63187-0379 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Mar 30, 2023 | In Use | |
| 65977-5025-03 | 65977-5025 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jun 7, 2010 | In Use | |
| 47335-0893-87 | 47335-0893 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 13, 2014 | In Use | |
| 87628-0101-02 | 87628-0101 | Rolapitant | Varubi | 90.0 mg/1 | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oral | Sep 8, 2026 | In Use | |
| 55513-0004-01 | 55513-0004 | Darbepoetin alfa | Aranesp | 60.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sep 11, 2006 | In Use | ||
| 63187-0243-30 | 63187-0243 | Prednisone | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sep 1, 2014 | In Use | |
| 10544-0915-10 | 10544-0915 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 20, 2015 | In Use | |
| 13668-0594-87 | 13668-0594 | APREPITANT | APREPITANT | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Oct 21, 2020 | In Use | |||
| 68083-0462-10 | 68083-0462 | Arsenic Trioxide | Arsenic Trioxide | 2.0 mg/mL | Chemotherapy | Miscellaneous Agent | PML/RARa | Intravenous | Oct 7, 2021 | In Use | |
| 43975-0252-05 | 43975-0252 | Temozolomide | Temozolomide | 5.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jul 13, 2016 | In Use | |
| 43975-0257-05 | 43975-0257 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jul 13, 2016 | In Use | |
| 47426-0201-01 | 47426-0201 | aprepitant | CINVANTI | 130.0 mg/18mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | Jan 3, 2018 | In Use | |
| 16729-0267-63 | 16729-0267 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct 22, 2013 | In Use | |
| 25021-0204-05 | 25021-0204 | Vinorelbine | Vinorelbine | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Vinca Alkaloid | Intravenous | Sep 15, 2014 | In Use | |
| 68382-0918-77 | 68382-0918 | methylprednisolone | methylprednisolone | 16.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | May 1, 2018 | In Use | |
| 61919-0326-20 | 61919-0326 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Sep 16, 2019 | In Use | |
| 42388-0025-37 | 42388-0025 | Cabozantinib | CABOMETYX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Feb 27, 2019 | In Use | |
| 68071-3394-06 | 68071-3394 | Estradiol | Estradiol | 1.0 mg/1 | Hormonal Therapy | Estrogen | Oral | Jul 12, 2017 | In Use | ||
| 71335-1628-08 | 71335-1628 | Prednisone | PREDNISONE | 5.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jan 28, 2022 | In Use | |
| 71205-0729-28 | 71205-0729 | PREDNISONE | Prednisone | 10.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Oct 31, 2024 | In Use | |
| 25021-0783-05 | 25021-0783 | palonosetron hydrochloride | palonosetron hydrochloride | 0.05 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jun 15, 2018 | In Use |
Found 12611 results — Export these results
Home